Brokerages forecast that Kamada Ltd (NASDAQ:KMDA) will post sales of $24.89 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Kamada’s earnings, with the lowest sales estimate coming in at $21.60 million and the highest estimate coming in at $28.17 million. Kamada reported sales of $11.65 million in the same quarter last year, which would suggest a positive year over year growth rate of 113.6%. The business is expected to announce its next quarterly earnings report on Tuesday, May 15th.
According to Zacks, analysts expect that Kamada will report full year sales of $24.89 million for the current financial year, with estimates ranging from $117.50 million to $129.28 million. For the next financial year, analysts anticipate that the business will post sales of $162.79 million per share, with estimates ranging from $139.80 million to $185.77 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Kamada.
Kamada (NASDAQ:KMDA) last issued its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.10. Kamada had a return on equity of 9.06% and a net margin of 6.71%. The firm had revenue of $35.71 million during the quarter, compared to the consensus estimate of $32.90 million.
Shares of KMDA stock remained flat at $$4.70 during trading on Wednesday. The company had a trading volume of 3,423 shares, compared to its average volume of 21,249. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.58 and a current ratio of 3.30. Kamada has a 52 week low of $3.75 and a 52 week high of $8.61. The stock has a market capitalization of $189.24, a price-to-earnings ratio of 27.65 and a beta of 1.12.
Hedge funds have recently added to or reduced their stakes in the business. ARK Investment Management LLC purchased a new stake in Kamada in the 4th quarter worth approximately $251,000. Vanguard Group Inc. grew its stake in Kamada by 6.5% in the 2nd quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock worth $2,810,000 after acquiring an additional 28,382 shares during the period. Analyst IMS Investment Management Services Ltd. grew its stake in Kamada by 125.5% in the 3rd quarter. Analyst IMS Investment Management Services Ltd. now owns 89,843 shares of the biotechnology company’s stock worth $431,000 after acquiring an additional 50,000 shares during the period. Meitav Dash Investments Ltd. purchased a new stake in Kamada in the 4th quarter worth approximately $3,512,000. Finally, Jane Street Group LLC purchased a new stake in Kamada in the 3rd quarter worth approximately $112,000. 9.14% of the stock is owned by hedge funds and other institutional investors.
WARNING: “Kamada Ltd (KMDA) Expected to Post Quarterly Sales of $24.89 Million” was posted by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/3303341/kamada-ltd-kmda-expected-to-post-quarterly-sales-of-24-89-million.html.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.